Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA

Judith Agudo

Department of Immunology, Harvard Medical School, Boston, MA, USA

Judith Agudo

Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA

Julio A. Aguirre-Ghiso

Cancer Dormancy & Tumour Microenvironment Institute at the Montefiore Einstein Comprehensive Cancer Center (MECCC), Albert Einstein College of Medicine, Bronx, NY, USA

Julio A. Aguirre-Ghiso

Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY, USA

Julio A. Aguirre-Ghiso

Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada

Mickie Bhatia

Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Lewis A. Chodosh

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Lewis A. Chodosh

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Lewis A. Chodosh

Champalimaud Research, Champalimaud Foundation, Lisbon, Portugal

Ana Luísa Correia

Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany

Christoph A. Klein

Division of Personalized Tumour Therapy, Fraunhofer ITEM-R, Regensburg, Germany

Christoph A. Klein

Judith Agudo: Judith Agudo is an Assistant Professor in the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and the Department of Immunology at Harvard Medical School. She is also a member researcher in both the Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute and the Ludwig Cancer Center at Harvard, and an affiliated member of the Harvard Stem Cell Institute and a New York Stem Cell Foundation–Robertson Investigator. The Agudo laboratory investigates mechanisms of immune evasion of cancer stem cells and quiescent cancer cells with the goal of identifying immune-based strategies to prevent metastasis.

Julio A. Aguirre-Ghiso: Julio A. Aguirre-Ghiso is the Rose Falkenstein Chair in Cancer Research, Professor of Cell Biology and Director of the Cancer Dormancy & Tumor Microenvironment Institute at Albert Einstein College of Medicine. His work led a paradigm shift, revealing novel cancer biology that diverges from the notion that cancer is perpetually proliferating. His team discovered that reciprocal crosstalk between disseminated tumour cells and the microenvironment regulates the inter-conversion between dormancy and metastasis initiation. His laboratory also provided a mechanistic understanding of the process of early dissemination and revealed how it contributes to dormancy and metastatic progression and how stress-adaptive pathways allow cancer cells to persist while quiescent.

Mickie Bhatia: Mickie Bhatia is a Professor at McMaster University, the Canada Research Chair in Human Stem Cell Biology, the Michael DeGroote Chair of Human Stem Cell Biology and Cancer Research and currently the Program Director of Experimental Therapeutics in human leukaemias. His program is integrated with several clinical sites and forms the hub for chemical genomics and drug discovery targeting putative cancer cells with stem cell properties. His laboratory was the first to culture pluripotent stem cell in Canada and leverages stem cell technologies and novel assay development for preclinical and translational phase I study in patients.

Lewis A. Chodosh: Lewis A. Chodosh is Perelman Professor and Chair of the Department of Cancer Biology at the Perelman School of Medicine at the University of Pennsylvania, Associate Director for Basic Science at the Abramson Cancer Center and, along with Angela DeMichele, co-founder and co-director of the 2-PREVENT Translational Center of Excellence, which is focused on developing novel approaches to prevent tumour recurrence in patients with breast cancer by targeting dormant minimal residual disease. His laboratory focuses on understanding mechanisms of tumour dormancy and recurrence, developing improved methods for detecting and characterizing disseminated tumour cells in patients, and leveraging those advances through clinical trials. He has been elected to the National Academy of Medicine, Association of American Physicians and American Society for Clinical Investigation.

Ana Luísa Correia: Ana Luísa Correia leads the Cancer Dormancy & Immunity Lab at the Champalimaud Foundation. Her group strives to understand what makes a tissue favourable or not to metastasis and leverages this biology into therapeutic interventions that reliably prevent the emergence of metastases in patients with cancer. Ana has received a few international awards (2021 Metastasis Research Prize, 2022 Pfizer Oncology and AACR 2022 NextGen Stars) and is an EMBO Young Investigator.

Christoph A. Klein: Christoph A. Klein studied Medicine at the Ludwig-MaximiliansUniversity in Munich. He is heading two laboratories, one at the University of Regensburg for basic metastasis research and one at the Fraunhofer Society for clinical translation of the results. The major focus of the said laboratories is on the earliest beginnings and mechanisms of metastatic spread and colonization.

Correspondence to Judith Agudo, Julio A. Aguirre-Ghiso, Mickie Bhatia, Lewis A. Chodosh, Ana Luísa Correia or Christoph A. Klein.